Navigation Links
Singapore research organisations team up to advance drug discovery using brain tumor stem cells
Date:2/17/2009

Lilly Singapore Centre for Drug Discovery (LSCDD), Singapore's National Neuroscience Institute (NNI), and the Singapore Institute for Clinical Sciences (SICS), have teamed up to advance drug discovery using adult brain tumour stem cells.

NNI is one of the institutions of SingHealth, the largest public healthcare group in Singapore. LSCDD, a wholly owned subsidiary of the US-based biopharmaceutical company, Eli Lilly and Company has recently expanded its facility at the Biopolis, and has cancer as one of its disease areas of focus. SICS is one of the research institutes of Singapore's A*STAR (Agency for Science, Technology and Research).

The research collaboration will leverage earlier findings by NNI research scientist Dr. Carol Tang, and Dr. Christopher Ang Beng Ti, a NNI neurosurgeon and SICS clinical investigator. The duo have shown that primary brain tumours are caused by a minority group of cells that display a genetic profile distinct from that of the tumour bulk.

They have reliably established a method of cryopreservation for these tumour-initiating cells (frequently termed "cancer stem cells"), thus facilitating the development of a brain tumour stem cell repository for future research and drug screening efforts. These important discoveries were published late last year in the journal Stem Cells. (http://www.a-star.edu.sg/biopolis/288-Press-Release?iid=576)

"Our scientific goals are to understand if and how we can target adult brain tumour stem cells selectively, and to use bioinformatics to identify novel biomarkers and new drug target," said Drs. Tang and Ang. "Ultimately, this could lead to new approaches to treat brain tumours."

The researchers have reason to be optimistic. This collaboration is the first amongst staff from Eli Lilly and Company and lead Singapore research agencies, NNI and A*STAR. With increased opportunities for exchanging ideas and synergising efforts, more effective and less invasive cancer treatment is now one step closer to becoming a reality.

Dr. Jonathon D. Sedgwick, LSCDD Managing Director and Chief Scientific Officer, said that "discovering new, breakthrough medicines through translational and clinical research requires intensive collaborations amongst partners. This research collaboration with clinicians and scientists from NNI and SICS will bring together different expertise and resources. This fits well with Lilly's new collaborative model known as the Fully Integrated Pharmaceutical Network (FIPNet) model, and will enhance and accelerate Lilly's ability to find 'Answers That Matter'."

Dr. Judith Swain, SICS Executive Director, said that "this collaboration is aligned with our focus on disease-oriented clinical and translational research. The family of clinician scientists here at SICS is well positioned to perform critical work at the border between basic and clinical research. We look forward to working closely with LSCDD and NNI to develop cutting-edge approaches for novel drug development."

"NNI's research aims to improve treatment and discover cures for neurological disease. This collaboration will enable all parties to benefit from the exchange of multidisciplinary expertise and will expedite the translation of research findings into clinical practice," said Prof. Lee Wei Ling, Executive Director of NNI.


'/>"/>

Contact: Cathy Yarbrough
sciencematter@yahoo.com
858-243-1814
Agency for Science, Technology and Research (A*STAR), Singapore
Source:Eurekalert

Related biology news :

1. Singapore National Science and Technology Awards
2. Phase 2 of Singapores Biomedical Sciences Initiative gains momentum for clinical research
3. Rare cancer-causing syndrome found, for the first time, in Singapore
4. Ludwig Institute for Cancer Research to set up its first Asian branch in Singapore
5. Singapores BIOPOLIS and FUSIONOPOLIS on stage in Boston this week
6. Singapore opens Fusionopolis, its second major R&D hub in 5 years
7. Singapore research team first place in Brain-Computer Interface contest
8. NTU undergrad is first Singapore champion of an internationally acclaimed engineering competition
9. Singapore-US scientists first to develop revolutionary microchip that uses 30 times less energy
10. Research shows skeleton to be endocrine organ
11. Newly created cancer stem cells could aid breast cancer research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/14/2016)... 2016 http://www.apimages.com ) - ... - Renvoi : image disponible via AP Images ... --> DERMALOG, le leader de ... lecteurs d,empreintes digitales pour l,enregistrement des réfugiés en ... pour produire des cartes d,identité aux réfugiés. DERMALOG ...
(Date:3/10/2016)... PUNE, India , March 10, 2016 ... to a new market research report "Identity and Access ... SSO, & Audit, Compliance, and Governance), by Organization Size, ... Forecast to 2020", published by MarketsandMarkets, The market is ... to USD 12.78 Billion by 2020, at a Compound ...
(Date:3/9/2016)... 2016 Nigeria . ... than 23,000 public service employees either did not exist ... salary unlawfully.    --> Nigeria ... more than 23,000 public service employees either did not ... their salary unlawfully.    --> DERMALOG, the ...
Breaking Biology News(10 mins):
(Date:5/4/2016)... ... May 04, 2016 , ... PBI-Gordon Corporation is pleased to announce Doug ... Doug began his career at PBI-Gordon in February 1988, after finishing his masters in ... roles, ranging from customer service to national product manager, to helping develop, name and ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... ... enterprise talent development, skill-building and compliance training platform on mobile devices, today ... course: Overview of Regulatory Requirements for Medical Devices. The course is essential for ...
(Date:5/3/2016)... ... 2016 , ... Flagship Biosciences, the leader in tissue ... of Directors. Dr. Gillett recently retired from Charles River Laboratories (CRL), where, in ... Officer. A board-certified veterinary pathologist, Dr. Gillett joined Charles River in 1999 through ...
(Date:5/3/2016)... -- - And Other Rising Companies - ... Competitor Biologics  - Biosimilar Drug Producers - ... Who are the most important and promising ... sales potentials? Discover, in our updated survey, organisations, outlooks ... revenue forecasting. Visiongain,s new study ...
Breaking Biology Technology: